CTLA4 and melanoma: While the combination of anti-4-1BB and anti-CTLA-4 antibodies produced tumor rejection in these two commonly less aggressive tumor types, the same therapy failed to produce tumor growth delay in the highly aggressive B16 melanoma model [25].